MacroGenics, Inc. (MGNX) News
Track canonical SquawkNews coverage tagged to MGNX, MacroGenics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Tri
MacroGenics, Inc. (NASDAQ: MGNX ), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exerc
EQUITY | Aug 11, 2026, 08:22 PM UTC
M
MGNX Achieves $10 Million Milestone
MGNX achieves $10 million milestone after Gilead exercises option to license preclinical bispecific program
MNA | Aug 11, 2026, 08:08 PM UTC
M
MGNX Receives $24.5M Milestone
MacroGenics to receive $24.5M milestone from Sanofi following FDA approval of TZIELD expansion in type 1 diabetes
EARNINGS | Jun 22, 2026, 08:45 PM UTC
M
MGNX Receives Milestone
MacroGenics to receive milestone payment from Sanofi for recent TZIELD approval
EQUITY | Jun 22, 2026, 08:43 PM UTC